70 related articles for article (PubMed ID: 34232002)
1. Understanding the Potential Role of Abrocitinib in the Time of SARS-CoV-2.
Uppal SK; Kearns DG; Chat VS; Wu JJ
J Drugs Dermatol; 2021 Jul; 20(7):806. PubMed ID: 34232002
[No Abstract] [Full Text] [Related]
2. Covid-19 and leptospirosis: Cytokine storm and the use of steroids.
Ittyachen AM
Trop Doct; 2021 Jan; 51(1):128-130. PubMed ID: 33236692
[TBL] [Abstract][Full Text] [Related]
3. Perspectives on Targeting IL-6 as a Potential Therapeutic Strategy for COVID-19.
Khaedir Y; Kartika R
J Interferon Cytokine Res; 2021 Feb; 41(2):37-43. PubMed ID: 33621130
[TBL] [Abstract][Full Text] [Related]
4. Acute respiratory distress syndrome and COVID-19 in a child with systemic lupus erythematosus.
Sukhdeo S; Negroponte E; Rajasekhar H; Gaur S; Horton DB; Malhotra A; Moorthy LN
Lupus; 2021 Apr; 30(5):836-839. PubMed ID: 33509065
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
6. Cytokine release syndrome in severe COVID-19.
Moore JB; June CH
Science; 2020 May; 368(6490):473-474. PubMed ID: 32303591
[No Abstract] [Full Text] [Related]
7. [Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19].
Muñoz-Jiménez A; Rubio-Romero E; Marenco de la Fuente JL
Reumatol Clin (Engl Ed); 2021; 17(6):309-312. PubMed ID: 32482538
[TBL] [Abstract][Full Text] [Related]
8. Nebulized Lidocaine in COVID-19, An Hypothesis.
Ali ZA; El-Mallakh RS
Med Hypotheses; 2020 Nov; 144():109947. PubMed ID: 32505070
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Simpson EL; Sinclair R; Forman S; Wollenberg A; Aschoff R; Cork M; Bieber T; Thyssen JP; Yosipovitch G; Flohr C; Magnolo N; Maari C; Feeney C; Biswas P; Tatulych S; Valdez H; Rojo R
Lancet; 2020 Jul; 396(10246):255-266. PubMed ID: 32711801
[TBL] [Abstract][Full Text] [Related]
10. Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury.
Tabassum N; Zhang H; Stebbing J
Cell Rep Med; 2020 Nov; 1(8):100145. PubMed ID: 33225317
[TBL] [Abstract][Full Text] [Related]
11. Can Beta-2-Adrenergic Pathway Be a New Target to Combat SARS-CoV-2 Hyperinflammatory Syndrome?-Lessons Learned From Cancer.
Barbieri A; Robinson N; Palma G; Maurea N; Desiderio V; Botti G
Front Immunol; 2020; 11():588724. PubMed ID: 33117402
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic plasma exchange in a critically ill Covid-19 patient.
Altmayer V; Saheb S; Rohaut B; Marois C; Cao A; Gallo A; Le Guennec L; Weiss N; Demeret S
J Clin Apher; 2021 Feb; 36(1):179-182. PubMed ID: 32875601
[TBL] [Abstract][Full Text] [Related]
13. Coronavirus Epidemic and Extracorporeal Therapies in Intensive Care: si vis pacem para bellum.
Ronco C; Reis T; De Rosa S
Blood Purif; 2020; 49(3):255-258. PubMed ID: 32172242
[No Abstract] [Full Text] [Related]
14. SARS-CoV-2 spike protein binds to bacterial lipopolysaccharide and boosts proinflammatory activity.
Petruk G; Puthia M; Petrlova J; Samsudin F; Strömdahl AC; Cerps S; Uller L; Kjellström S; Bond PJ; Schmidtchen AA
J Mol Cell Biol; 2020 Oct; 12(12):916-932. PubMed ID: 33295606
[TBL] [Abstract][Full Text] [Related]
15. Multiple potential targets of opioids in the treatment of acute respiratory distress syndrome from COVID-19.
Cismaru CA; Cismaru GL; Nabavi SF; Ghanei M; Burz CC; Nabavi SM; Berindan Neagoe I
J Cell Mol Med; 2021 Jan; 25(1):591-595. PubMed ID: 33211389
[TBL] [Abstract][Full Text] [Related]
16. Empirical treatment with epithelial growth factor receptor tyrosine kinase inhibitor for neoplastic acute respiratory distress syndrome.
Contou D; Raynaud-Donzel C
Minerva Anestesiol; 2020 Feb; 86(2):218-220. PubMed ID: 31486626
[No Abstract] [Full Text] [Related]
17. Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
Gooderham MJ; Forman SB; Bissonnette R; Beebe JS; Zhang W; Banfield C; Zhu L; Papacharalambous J; Vincent MS; Peeva E
JAMA Dermatol; 2019 Dec; 155(12):1371-1379. PubMed ID: 31577341
[TBL] [Abstract][Full Text] [Related]
18. [The neurology of COVID-19].
Cuevas-García C; Calderón-Vallejo A; Berrón-Ruiz L
Rev Alerg Mex; 2020; 67(4):338-349. PubMed ID: 33631902
[TBL] [Abstract][Full Text] [Related]
19. Recombinant tissue plasminogen activator treatment for COVID-19 associated ARDS and acute cor pulmonale.
Kosanovic D; Yaroshetskiy AI; Tsareva NA; Merzhoeva ZM; Trushenko NV; Nekludova GV; Schermuly RT; Avdeev SN
Int J Infect Dis; 2021 Mar; 104():108-110. PubMed ID: 33352323
[TBL] [Abstract][Full Text] [Related]
20. IL-17A and TNF-α as potential biomarkers for acute respiratory distress syndrome and mortality in patients with obesity and COVID-19.
Leija-Martínez JJ; Huang F; Del-Río-Navarro BE; Sanchéz-Muñoz F; Muñoz-Hernández O; Giacoman-Martínez A; Hall-Mondragon MS; Espinosa-Velazquez D
Med Hypotheses; 2020 Nov; 144():109935. PubMed ID: 32795834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
